A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Seagen Inc.
With
Millennium Pharmaceuticals, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with HL who have received ASCT in the previous 30-45 days
Patients at high risk of residual HL post ASCT
Histologically-confirmed HL
ECOG of 0 or 1
Adequate organ function
You may not be if
Previous treatment with brentuximab vedotin
Previously received an allogeneic transplant
Patients who were determined to have a best clinical response of progressive disease with salvage treatment immediately prior to ASCT
History of another primary malignancy that has not been in remission for at least 3 years
Post ASCT or current therapy with other systemic anti-neoplastic or investigational agents
Clareo Health | A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
